on Theranexus (EPA:ALTHX)
THX Pharma Announces Strong Cash Position at Year-End
On February 19, 2026, THX Pharma, a biopharmaceutical firm focused on rare neurological diseases, reported a significant cash position of €7,764 thousand as of December 31, 2025. This marks a substantial increase from €1,979 thousand at the end of September 2025. The company anticipates an additional €12 million payment from Biocodex in March 2026, enhancing its financial standing to a pro forma cash position of €21.7 million.
According to CEO Mathieu Charvériat, the company controlled expenses and secured nearly €8 million in funding throughout 2025. The Biocodex agreement will fully finance the ongoing development of the Batten-1 program, with commercialization projected for 2029. THX Pharma is also progressing with TX01, aiming for regulatory filings this year and commercialization by 2027 through partners Biocodex and Exeltis.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news